Literature DB >> 25556114

Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa.

David G Birch1, Kirsten G Locke2, Joost Felius3, Martin Klein2, Dianna K H Wheaton3, Dennis R Hoffman3, Donald C Hood4.   

Abstract

PURPOSE: To determine whether annual decline in visual field sensitivity is greater in the transition zone at the edge of the frequency-domain optical coherence tomography (fdOCT) inner segment ellipsoid zone (EZ) than at other locations in the visual field.
DESIGN: Prospective, longitudinal, observational study. PARTICIPANTS: Forty-four patients with X-linked retinitis pigmentosa (XLRP) resulting from a mutation in the RPGR gene.
METHODS: Static perimetric fields (Humphrey 30-2; Carl Zeiss Meditec, Dublin, CA) were obtained annually for 4 years. Beginning with year 2, fdOCT scans were obtained annually with a Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany). MAIN OUTCOME MEASURES: The rate of visual field decline at locations near the edge of the EZ compared with the rates for the macula and in the mid periphery.
RESULTS: Sensitivity just inside and outside the edge of the EZ declined at rates of 0.84 and 0.92 dB/year, respectively. By comparison, average sensitivity in the macula and mid periphery declined by 0.38 and 0.61 dB/year, respectively.
CONCLUSIONS: The edge of the EZ in each patient with XLRP indicates a transition zone between relatively healthy and relatively degenerate retina. The annual loss of sensitivity in the transition zone is more rapid than it is elsewhere in the retina.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25556114      PMCID: PMC4372456          DOI: 10.1016/j.ophtha.2014.11.005

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

1.  Transition zones between healthy and diseased retina in choroideremia (CHM) and Stargardt disease (STGD) as compared to retinitis pigmentosa (RP).

Authors:  Margot A Lazow; Donald C Hood; Rithambara Ramachandran; Tomas R Burke; Yi-Zhong Wang; Vivienne C Greenstein; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-20       Impact factor: 4.799

2.  Ultrahigh resolution optical coherence tomography and pancorrection for cellular imaging of the living human retina.

Authors:  Enrique J Fernández; Boris Hermann; Boris Povazay; Angelika Unterhuber; Harald Sattmann; Bernd Hofer; Peter K Ahnelt; Wolfgang Drexler
Journal:  Opt Express       Date:  2008-07-21       Impact factor: 3.894

3.  Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A.

Authors:  Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Robert J Brockhurst; K C Hayes; Elizabeth J Johnson; Ellen J Anderson; Chris A Johnson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer
Journal:  Arch Ophthalmol       Date:  2010-04

4.  Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thicknesses in patients with retinitis pigmentosa.

Authors:  Yuquan Wen; Martin Klein; Donald C Hood; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

5.  Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa.

Authors:  William Seiple; Colleen J Clemens; Vivienne C Greenstein; Ronald E Carr; Karen Holopigian
Journal:  Doc Ophthalmol       Date:  2004-11       Impact factor: 2.379

6.  Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa.

Authors:  David G Birch; Kirsten G Locke; Yuquan Wen; Kelly I Locke; Dennis R Hoffman; Donald C Hood
Journal:  JAMA Ophthalmol       Date:  2013-09       Impact factor: 7.389

7.  Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.

Authors:  Dennis R Hoffman; Dianna K Hughbanks-Wheaton; N Shirlene Pearson; Gary E Fish; Rand Spencer; Alison Takacs; Martin Klein; Kirsten G Locke; David G Birch
Journal:  JAMA Ophthalmol       Date:  2014-07       Impact factor: 7.389

8.  A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa.

Authors:  Dennis R Hoffman; Kirsten G Locke; Dianna H Wheaton; Gary E Fish; Rand Spencer; David G Birch
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

9.  Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography.

Authors:  Donald C Hood; Christine E Lin; Margot A Lazow; Kirsten G Locke; Xian Zhang; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-14       Impact factor: 4.799

10.  A Comparison of Methods for Tracking Progression in X-Linked Retinitis Pigmentosa Using Frequency Domain OCT.

Authors:  Rithambara Ramachandran; Lisa Zhou; Kirsten G Locke; David G Birch; Donald C Hood
Journal:  Transl Vis Sci Technol       Date:  2013-11-11       Impact factor: 3.283

View more
  30 in total

1.  Digenic heterozygous mutations in EYS/LRP5 in a Chinese family with retinitis pigmentosa.

Authors:  Feng-Juan Gao; Sheng-Hai Zhang; Jun-Yi Chen; Ge-Zhi Xu; Ji-Hong Wu
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

2.  Inner segment ellipsoid band length is a prognostic factor in retinitis pigmentosa associated with EYS mutations: 5-year observation of retinal structure.

Authors:  M Miyata; K Ogino; N Gotoh; S Morooka; T Hasegawa; M Hata; N Yoshimura
Journal:  Eye (Lond)       Date:  2016-08-26       Impact factor: 3.775

3.  Time Course of Disease Progression of PRPF31-mediated Retinitis Pigmentosa.

Authors:  Kelly Kiser; Kaylie D Webb-Jones; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; David G Birch
Journal:  Am J Ophthalmol       Date:  2018-12-21       Impact factor: 5.258

4.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

Authors:  William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

5.  Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial.

Authors:  Dennis R Hoffman; Dianna K Hughbanks-Wheaton; Rand Spencer; Gary E Fish; N Shirlene Pearson; Yi-Zhong Wang; Martin Klein; Alison Takacs; Kirsten G Locke; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

6.  Visual and morphological outcomes of vitreomacular traction syndrome in retinitis pigmentosa treated by vitrectomy.

Authors:  Feng Yan; Feng-Jie Xia; Feng Jiang; Hyeong Gon Yu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

Review 7.  Aberrant protein trafficking in retinal degenerations: The initial phase of retinal remodeling.

Authors:  Katie L Bales; Alecia K Gross
Journal:  Exp Eye Res       Date:  2015-11-26       Impact factor: 3.467

8.  Variegated yet non-random rod and cone photoreceptor disease patterns in RPGR-ORF15-associated retinal degeneration.

Authors:  Jason Charng; Artur V Cideciyan; Samuel G Jacobson; Alexander Sumaroka; Sharon B Schwartz; Malgorzata Swider; Alejandro J Roman; Rebecca Sheplock; Manisha Anand; Marc C Peden; Hemant Khanna; Elise Heon; Alan F Wright; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

Review 9.  Promises and pitfalls of evaluating photoreceptor-based retinal disease with adaptive optics scanning light ophthalmoscopy (AOSLO).

Authors:  Niamh Wynne; Joseph Carroll; Jacque L Duncan
Journal:  Prog Retin Eye Res       Date:  2020-11-06       Impact factor: 19.704

Review 10.  Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives.

Authors:  Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson
Journal:  Prog Retin Eye Res       Date:  2019-12-30       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.